The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 5
- 3 new, 2 renewals
- Median first-year cost
- $1,622,725
- $7,950,922 in all
- Institutions
- 5
- 5 contact PIs
- Patents
- 4
- from 1 funded project
Awards by fiscal year
Fiscal years 2014 to 2026.
Most frequent institutions
- STATE UNIVERSITY OF NY,BINGHAMTON1
- UNIVERSITY OF ILLINOIS AT CHICAGO1
- UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR1
- UNIVERSITY OF SOUTHERN CALIFORNIA1
- VIRGINIA COMMONWEALTH UNIVERSITY1
Most frequent study sections
- Special Emphasis Panel (ZAA1 GG (50))5
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2015 | Center for Alcohol Research in Epigenetics1P50AA022538-01 | Pandey, Subhash C. | UNIVERSITY OF ILLINOIS AT CHICAGO, IL | First-year cost $1,622,725 | Study section ZAA1 |
| FY2014 | Developmental Exposure Alcohol Research Center2P50AA017823-06 | Spear, Linda Patia | STATE UNIVERSITY OF NY,BINGHAMTON, NY | First-year cost $1,650,586 | Study section ZAA1 |
| FY2014 | Southern California Research Center for ALPD and Cirrhosis2P50AA011999-16 | Tsukamoto, Hidekazu | UNIVERSITY OF SOUTHERN CALIFORNIA, CA | First-year cost $1,627,974 | Study section ZAA1 |
| FY2014 | Fetal ethanol-induced behavioral deficits: Mechanisms, diagnosis and Intervention1P50AA022534-01 | Savage, Daniel D. | UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR, NM | First-year cost $1,618,836 | Study section ZAA1 |
| FY2014 | Cross-Species Investigation of Gene Networks for Ethanol-Related Behaviors1P50AA022537-01 | Kendler, Kenneth Seedman | VIRGINIA COMMONWEALTH UNIVERSITY, VA | First-year cost $1,430,801 | Study section ZAA1 |
Patents from its funded projects
4 patents name 1 of the 5 funded projects.
- US 12,048,679 (opens the patent at USPTO, a PDF, in a new tab)P53-DESTABILIZING PROTEIN ASSOCIATED WITH PROTO-ONCOGENE STEMNESS AS A THERAPEUTIC TARGET AND INHIBITORS THEREOF FOR USE IN TREATMENT OF CANCERGranted July 30, 2024 to University of Southern CaliforniaP50AA011999 · UNIVERSITY OF SOUTHERN CALIFORNIA, CA
- US 10,245,298 (opens the patent at USPTO, a PDF, in a new tab)Compositions and Methods for Treating FibrosisGranted April 2, 2019 to CEDARS-SINAI MEDICAL CENTER and The Board of Trustees of the Leland Stanford Junior UniversityP50AA011999 · UNIVERSITY OF SOUTHERN CALIFORNIA, CA
- US 10,233,240 (opens the patent at USPTO, a PDF, in a new tab)Origin of myofibroblasts in fibrotic liverGranted March 19, 2019 to THE REGENTS OF THE UNIVERSITY OF CALIFORNIAP50AA011999 · UNIVERSITY OF SOUTHERN CALIFORNIA, CA
- US 6,953,786 (opens the patent at USPTO, a PDF, in a new tab)FOOD-DERIVED POLYPHENOLIC COMPOUNDS AND INHIBITORS OF REACTIVE OXYGEN SPECIES IN THE TREATMENT OF PANCREATIC CANCERGranted October 11, 2005 to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA and Department of Veterans AffairsP50AA011999 · UNIVERSITY OF SOUTHERN CALIFORNIA, CA
Each number opens the patent at USPTO, beside the project NIH ties it to and that project's institution. NIH ties a patent to a project, not to a year of its funding, and says its list is incomplete. The grant date and the owners are USPTO's: the organizations the patent names as assignees on the day it was granted. Source: United States Patent and Trademark Office, www.uspto.gov, which does not endorse ScienceDex.
Data: Grants.gov's daily extract and NIH's notice pages, award files and patents file, in ScienceGraph release conductgrants-2026-11-13-0.3.2. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.